Clinical Trials
Clinical Trials of Investigational Medical Products (CTIMPs) for Wilson’s Disease
Comprehensive details about Clinical Trials, past, present and future, can be accessed through the website https://clinicaltrials.gov/. Simply type “Wilson’s disease” into the box where it asks for Condition/Disease.
Recruiting:
Orphalan – Phase 2 Study – Once a Day dosing of Trientine Tetrahydrochloride vs Standard of Care (SOC – i.e. a patient’s current medication).
This Study is now live on https://clinicaltrials.gov/ and has the ID number NCT07010575.
Recruitment is underway for an 8 week study to explore Wilson’s disease patients’ opinion on a new trientine formulation taken once a day vs SOC.
If you are aged 18 or older, have a Wilson’s disease diagnosis, take and have taken for at least 3 months no more than 1200 mg a day in divided doses of a WD chelating medication (i.e. penicillamine or a trientine product) and use contraception if you are sexually active, you may be eligible to participate in this Study.
This Study is run by a Virtual Clinical Research Centre (VCTC). For further information, please telephone the VCTC on 01332 429760 (option 3) or email them on information@thevctc.com.
Disclaimer:
All Clinical Trial Studies shared on this website are provided to help patients and caregivers stay informed about ongoing developments. Inclusion of a study on our website does not imply endorsement by WDSG-UK. We encourage all patients to consult their healthcare providers when interpreting medical information and/or making decisions about applying to take part in any trials advertised.
